Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-booster antibody responses in UK infants after reduced priming schedules of MenB and PCV13 vaccines
2015-000817-32Phase 4Unknown
- Sponsor
- University of Oxford
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of meningococcal group B vaccine and pneumococcal 13-valent conjugate vaccine in meningococcal disease and pneumococcal disease (2 arms), sponsored by University of Oxford. Primary endpoint: Post-booster pneumococcal antibody levels at about 13 months. Status: unknown.
02
Drugs
meningococcal group B vaccinepneumococcal 13-valent conjugate vaccine
03
Conditions
meningococcal diseasepneumococcal disease
Beyond the preview
Go deeper on 2015-000817-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000817-32.